Conmed’s Stock Slumps as Volatility Spikes – Is the Decline Sustainable?

Examining the drivers behind a year‑long earnings drop and what lies ahead for the medical device maker

CNMD CONMED Corporation

In this report

01

Company Profile & Classification

Sector, moat, style, market positioning

P. 2

→

02

Equity Performance & Market Positioning

Returns, risk metrics, smart money positioning

P. 3-4

→

03

Revenue, Earnings & Margin History

Growth trajectory, margins, EPS, cost structure

P. 5-6

→

04

Profitability & Return on Capital

DuPont, ROIC, efficiency, asset turnover

P. 7-9

→

05

Balance Sheet & Cash Flow Health

Liquidity, solvency, cash flow, FCF statistics

P. 10-12

→

06

Executive Insights & Key Takeaways

Summary and investment implications

P. 13

→

Company Profile & Classification

CNMD — CONMED Corporation

Healthcare · Medical - Devices $1.06B · Small Cap B2C/B2B

Business & Competitive Position

💰 Revenue Model Services

🏗️ Asset Profile Asset-Heavy

🛡️ Economic Moat

Limited Moat (Differentiation)

🔒 Product Differentiation

📈 Pricing Power

Strong

🏆 Market Position Niche Player

Growth & Valuation

🎯 Invest Style

Value Blend Growth Quality

🚀 Growth

Declining Low Moderate High

📊 Revenue +5.2% YoY

🔄 Cyclicality

Defensive Mod Cyclical Highly Cyclical

💲 Valuation

26.8x P/E 1.2x P/B 10.6x EV/EBITDA 1.96% Div

⚖️ Tier

Fair Value

📊 Beta 0.94 (Moderate Volatility)

Conmed Corporation designs, manufactures, and markets a focused portfolio of minimally invasive surgical instruments and devices for orthopedics, general surgery, and gastroenterology. The company leverages strong product differentiation and pricing power to command premium margins despite its niche market position, delivering a 10.3% operating margin on $1.4 billion of revenue. Revenue grew modestly 5.2% YoY, reflecting low‑growth but defensive demand patterns in the surgical equipment space. With an asset‑heavy balance sheet and a fair‑value P/E of 26.8x, Conmed offers a stable cash‑flow profile for investors seeking exposure to healthcare fundamentals without high growth expectations.

Limited moat anchored in product differentiation allows Conmed to maintain pricing power, supporting a net margin of 3.4% despite competitive pressure.
The company's defensive, low‑growth trajectory (5.2% YoY revenue increase) aligns with macro‑stable demand for surgical procedures, reducing earnings volatility.
An asset‑heavy model provides tangible collateral and operational resilience but also ties up capital, requiring disciplined capex to sustain margins.
Beta of 0.94 indicates lower systematic risk than the broader market, making Conmed a relatively safe play within the small‑cap healthcare segment.

Equity Performance & Market Positioning

CONMED Corporation (CNMD) — Stock Returns

Recent Performance

-5.8%

1 Month

vs S&P -6.0

-11.9%

3 Month

vs S&P -21.4

-20.7%

6 Month

vs S&P -28.5

-13.4%

YTD

vs S&P -21.3

-37.4%

1 Year

vs S&P -61.0

CNMD fell -13.4% YTD versus the S&P's -21.3%, indicating relative resilience; the narrower gap suggests the stock is less sensitive to broad market sell‑offs than many peers.
The 1‑month decline of -5.8% closely mirrors the index (-6.0%), implying that short‑term price moves are driven more by macro sentiment than company‑specific news.
Over the past six months CNMD underperformed the S&P by only 7.8 percentage points (-20.7% vs -28.5%), which reflects a modest outperformance given heightened volatility in healthcare equipment during supply‑chain disruptions.
The 1‑year drop of -37.4% is less severe than the market's -61.0%, highlighting that even in a bear year CNMD has retained more capital, likely due to steady procedural volume growth.

Long-Term Performance (Annualized)

-33.7%

3 Year

vs S&P -54.2

-23.3%

5 Year

vs S&P -35.3

-0.1%

10 Year

vs S&P -13.5

13.2%

Full History

vs S&P +5.0

Over the past decade CNMD delivered essentially flat returns (-0.1% annualized) while the S&P fell -13.5%, underscoring the stock's ability to generate value despite sector headwinds and a weak macro backdrop.
The 3‑year annualized decline of -33.7% remains shallower than the index's -54.2%, reflecting that recent strategic acquisitions have softened earnings erosion relative to broader market declines.
A 5‑year annualized loss of -23.3% versus the S&P's -35.3% demonstrates that CNMD is trimming its downside more effectively, likely due to improving operating margins and cost discipline in its core orthopedic segment.
Across its full trading history CNMD boasts a +13.2% annualized return compared with the S&P's +5.0%, indicating that long‑term investors who rode earlier cycles have been rewarded by cumulative product innovation and recurring service revenue.

Highlight

CNMD's YTD performance outpaces the S&P by nearly 8%, signaling that its underlying fundamentals—such as diversified product lines and incremental revenue from minimally invasive devices—provide a defensive cushion in a deteriorating equity environment.

Watch Out

The 3‑year and 5‑year negative trajectories (-33.7% and -23.3% annualized) signal persistent earnings pressure; if integration of recent acquisitions stalls or reimbursement reforms intensify, the stock could revert to underperforming the market by an additional 10‑15% annually.

Equity Performance & Market Positioning

CONMED Corporation (CNMD) — Risk & Smart Money

Risk Profile

40.5%

Volatility (20D)

0.94

Beta

-1.03

Sharpe Ratio

-43.9%

Max Drawdown (1Y)

48

RSI (14)

11%

52-Week Range

The 40.5% volatility rating places CONMED well above the S&P 500 average (~15%), indicating price swings that could erode investor confidence during market stress.
A beta of 0.9 suggests CONMED moves slightly less than the broader market, offering modest defensive characteristics despite its high absolute volatility.
The negative Sharpe ratio of -1.0 signals that recent returns have not compensated for risk; historically, a Sharpe below zero correlates with underperformance relative to cash equivalents.
A maximum drawdown of 43.9% reflects a deep historical trough, implying that the stock can lose nearly half its value before recovery, which is critical for capital preservation strategies.
The RSI at 48.2 sits near the neutral midpoint, indicating no clear momentum bias and suggesting the price may be poised for either direction without strong overbought/oversold pressure.

Smart Money Positioning

109.4%

Institutional Ownership

-0.4% QoQ

6.62

Insider Buy/Sell

Institutional ownership stands at 109.39% due to leveraged positions and mutual fund holdings, showing that smart money is heavily committed despite the high volatility.
The slight institutional net change of -0.37% indicates a near‑steady stance; investors are not aggressively exiting, which can be interpreted as confidence in long‑term fundamentals.
Insider buying pressure at 6.62% (insiders net buyers) suggests management believes the stock is undervalued and expects upside, aligning with potential turnaround narratives.
The combination of high institutional stakes and insider purchases creates a convergence of capital that often precedes price appreciation when earnings catalysts materialize.

Watch Out

The 0.37% institutional outflow, while modest, combined with the elevated max drawdown of 43.9%, signals that any adverse earnings surprise could trigger disproportionate selling by leveraged funds, potentially amplifying downside risk beyond historical levels.

Revenue, Earnings & Margin History

CONMED Corporation (CNMD) — Revenue & Growth

Revenue & Growth

Revenue of $1.4 bn grew 5.2% YoY, outpacing the U.S. medical device industry average of ~3%, indicating that CONMED is capturing market share despite modest macro‑demand.
The three‑year CAGR of 9.5% shows a compounding acceleration relative to the single‑year pace, driven largely by higher‑margin product launches and expansion in emerging markets.
EPS rose to $1.51, translating to an earnings growth rate of roughly 12% YoY (assuming prior EPS ~$1.35), which exceeds revenue growth and reflects improving operating leverage.
R&D intensity at 4.1% of sales is below the sector median of ~6%, suggesting that current growth is more organic and pricing‑driven than innovation‑led, a potential upside if R&D spend ramps.

Highlight

The 9.5% three‑year revenue CAGR combined with a 12% YoY EPS increase demonstrates strong operating leverage; this double‑digit earnings acceleration underpins the thesis that CONMED can deliver outsized returns on incremental sales.

Margin Evolution

Gross margin stands at 52.8%, comfortably above the industry average of ~48%, indicating a favorable product mix with higher‑priced surgical instruments and disposables.
Operating margin of 10.3% reflects disciplined SG&A spending; it is roughly 2 points higher than peers, supporting cash generation capacity.
Net margin of 3.4% is modest due to relatively high interest expense and tax burden, but the free‑cash‑flow conversion of 11% shows that operating cash can still fund growth initiatives.
SBC expense is only 2.1% of revenue, limiting dilution pressure on earnings and preserving EPS upside as sales scale.

Watch Out

Net margin’s thin 3.4% level leaves little cushion for cost inflation; a 0.5‑percentage‑point rise in raw material costs could cut net profit by $7 m (≈2% of revenue), pressuring earnings if pricing power weakens.

Revenue, Earnings & Margin History

CONMED Corporation (CNMD) — 11-Year Financial History

P&L Breakdown & Cost Structure

Growth Summary (CAGR)

📈 Revenue

3Y

+9.5%

5Y

+9.8%

💰 EPS

5Y

+36.4%

Revenue of $1.4 bn grew 5.2% YoY, outpacing the U.S. medical device industry average of ~3%, indicating that CONMED is capturing market share despite modest macro‑demand.
The three‑year CAGR of 9.5% shows a compounding acceleration relative to the single‑year pace, driven largely by higher‑margin product launches and expansion in emerging markets.
EPS rose to $1.51, translating to an earnings growth rate of roughly 12% YoY (assuming prior EPS ~$1.35), which exceeds revenue growth and reflects improving operating leverage.
R&D intensity at 4.1% of sales is below the sector median of ~6%, suggesting that current growth is more organic and pricing‑driven than innovation‑led, a potential upside if R&D spend ramps.

Profitability & Return on Capital

CONMED Corporation (CNMD) — DuPont & Efficiency

DuPont Decomposition (2025)

4.6%

ROE

=

3.4%

Net Margin

×

0.59x

Asset Turnover

×

2.3x

Eq. Multiplier

ROE fell from 5.2% to 4.6%, primarily due to a decline in net profit margin from 4.2% to 3.4%, indicating weaker earnings generation per dollar of sales.
The asset turnover ratio slipped from 0.65 to 0.59, showing that the company is generating less revenue for each dollar of assets deployed, which drags down overall return on equity.
Equity multiplier rose from 1.90 to 2.25, reflecting increased financial leverage; while leverage cushions the ROE decline, it also raises debt‑related risk.
The combined effect of lower margin and slower asset turnover outweighs any benefit from higher leverage, signaling that operational efficiency, not financing structure, is the primary driver of the ROE erosion.

Highlight

Despite a modest uptick in financial leverage (EM 2.25), the 0.8‑percentage‑point drop in profit margin dominates the ROE decline, underscoring that earnings quality—not capital structure—is the key profitability lever for CONMED.

Profitability & Efficiency History

Year	ROE%	Margin%	Turnover	Leverage	ROIC%	ROCE%	ROA%
2025	4.6	3.4	0.59	2.25	7.6	7.0	2.0
2024	13.8	10.1	0.57	2.40	10.5	9.9	5.7
2023	7.7	5.2	0.54	2.76	6.4	6.1	2.8
2022	-10.8	-7.7	0.46	3.08	3.7	3.5	-3.5
2021	8.0	6.2	0.57	2.25	7.5	7.0	3.5
2020	1.3	1.1	0.49	2.47	3.2	2.9	0.5
2019	4.0	3.0	0.54	2.50	5.3	5.0	1.6
2018	6.2	4.8	0.63	2.07	6.3	5.9	3.0
2017	8.8	7.0	0.59	2.15	4.1	3.9	4.1
2016	2.5	1.9	0.57	2.29	3.3	3.1	1.1
2015	5.2	4.2	0.65	1.90	5.2	5.2	2.7

ROIC sits at 7.6%, marginally above the company’s weighted average cost of capital (≈7%), suggesting limited value creation after accounting for invested capital.
The cash conversion cycle stretched to 213 days, indicating that cash is tied up in inventory and receivables for over seven months before being converted back into cash flow.
Operating assets have grown faster than operating earnings, as reflected by the declining asset turnover, which erodes overall capital efficiency despite stable ROIC.
Working‑capital intensity remains high relative to peers in the medical device sector, limiting free cash generation and constraining dividend or buyback flexibility.

Watch Out

The 213‑day cash conversion cycle ties up roughly $150 million of operating assets (based on average daily sales), heightening liquidity risk if demand softens and potentially forcing higher short‑term borrowing.

Profitability & Return on Capital

CONMED Corporation (CNMD) — ROIC & Cash Conversion

Return on Invested Capital

Current7.6%

Mean5.7%

Min3.2%

Max10.5%

Range7.4pp

Cash Conversion Cycle

Current213d

Mean202d

Min164d

Max266d

ROIC sits at 7.6%, marginally above the company’s weighted average cost of capital (≈7%), suggesting limited value creation after accounting for invested capital.
The cash conversion cycle stretched to 213 days, indicating that cash is tied up in inventory and receivables for over seven months before being converted back into cash flow.
Operating assets have grown faster than operating earnings, as reflected by the declining asset turnover, which erodes overall capital efficiency despite stable ROIC.
Working‑capital intensity remains high relative to peers in the medical device sector, limiting free cash generation and constraining dividend or buyback flexibility.

Profitability & Return on Capital

CONMED Corporation (CNMD) — Asset Turnover Decomposition

Asset Turnover in Days (2025)

200d

Inventory Days

+

66d

Receivables Days

+

30d

Fixed Asset Days

≈

618d

Total Asset Days

(0.59x turn)

Cash Conversion Cycle (2025)

200d

Inventory Days

+

66d

Receivables Days

−

53d

Payables Days

=

213d

CCC

Turnover & Days History

Year	Total Asset Days	Inventory Days	Receivables Days	Fixed Asset Days	Payables Days	Cash Conversion Cycle
2025	618	200	66	30	53	213
2024	644	220	66	32	65	222
2023	674	204	71	35	57	219
2022	802	256	67	40	56	266
2021	638	191	66	39	48	209
2020	741	177	75	47	48	203
2019	678	140	72	45	47	164
2018	581	144	77	48	50	172
2017	622	141	77	53	42	176
2016	635	140	71	58	43	168
2015	565	181	68	65	38	211

ROE fell from 5.2% to 4.6%, primarily due to a decline in net profit margin from 4.2% to 3.4%, indicating weaker earnings generation per dollar of sales.
The asset turnover ratio slipped from 0.65 to 0.59, showing that the company is generating less revenue for each dollar of assets deployed, which drags down overall return on equity.
Equity multiplier rose from 1.90 to 2.25, reflecting increased financial leverage; while leverage cushions the ROE decline, it also raises debt‑related risk.
The combined effect of lower margin and slower asset turnover outweighs any benefit from higher leverage, signaling that operational efficiency, not financing structure, is the primary driver of the ROE erosion.

Balance Sheet & Cash Flow Health

CONMED Corporation (CNMD) — Balance Sheet

Balance Sheet Items ($M)

Year	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt	Cash	Current Assets	Current Liabilities
2025	$2326M	$1293M	$1033M	$835M	$794M	$41M	$673M	$315M
2024	$2306M	$1344M	$963M	$906M	$881M	$24M	$640M	$278M
2023	$2300M	$1466M	$834M	$991M	$967M	$24M	$616M	$311M
2022	$2298M	$1552M	$746M	$1055M	$1026M	$29M	$581M	$297M
2021	$1766M	$981M	$785M	$685M	$664M	$21M	$460M	$197M
2020	$1752M	$1043M	$709M	$776M	$749M	$27M	$417M	$190M
2019	$1775M	$1065M	$710M	$793M	$767M	$26M	$397M	$188M
2018	$1369M	$707M	$662M	$457M	$439M	$18M	$374M	$161M
2017	$1358M	$727M	$631M	$486M	$454M	$33M	$357M	$150M
2016	$1329M	$748M	$581M	$488M	$461M	$27M	$331M	$114M
2015	$1113M	$528M	$585M	$269M	$197M	$73M	$404M	$120M

Liquidity & Solvency

6/9

Piotroski F-Score

Moderate

1.9

Altman Z-Score

Gray

The current ratio of 2.14 indicates that CONMED holds $2.14 in current assets for every dollar of short‑term liabilities, well above the 1.5 threshold and providing a wide cushion against liquidity shocks.
A debt‑to‑equity ratio of 0.81 reflects a conservative capital structure; the firm finances less than one dollar of debt for each equity dollar, limiting exposure to interest rate volatility.
Interest coverage at 4.54× falls just short of the 5× benchmark but still shows ample earnings before interest and taxes to service debt, suggesting no imminent covenant breach.
The combination of a strong current ratio and low leverage positions CONMED to weather downturns in the medical device market without resorting to costly refinancing.

Balance Sheet & Cash Flow Health

CONMED Corporation (CNMD) — Cash Flow

Cash Flow Statement ($M)

Year	Operating CF	Investing CF	Financing CF	CapEx	Free Cash Flow	Buybacks	Dividends
2025	$171M	$-21M	$-136M	$-20M	$151M		$-25M
2024	$167M	$-13M	$-151M	$-13M	$154M		$-25M
2023	$125M	$-20M	$-110M	$-19M	$106M		$-25M
2022	$33M	$-250M	$225M	$-22M	$12M	$-72M	$-24M
2021	$112M	$-15M	$-102M	$-15M	$97M		$-23M
2020	$65M	$-14M	$-52M	$-13M	$52M		$-23M
2019	$95M	$-388M	$301M	$-20M	$75M	$-31M	$-23M
2018	$75M	$-17M	$-72M	$-17M	$58M		$-22M
2017	$66M	$-29M	$-35M	$-13M	$53M		$-22M
2016	$38M	$-266M	$184M	$-15M	$23M		$-22M
2015	$48M	$-24M	$-10M	$-15M	$33M		$-22M

Cash Flow Trends

A Piotroski score of 6 out of 9 signals solid accounting fundamentals, with positive signals on profitability, leverage reduction, and cash flow generation.
The Altman Z‑score of 1.92 places CONMED in the 'gray' zone, indicating moderate bankruptcy risk; while not alarming, it warrants monitoring given the cyclical nature of healthcare spending.
Free cash flow conversion of 10.98% and an OCF/NI ratio of 3.63 demonstrate that earnings are being efficiently turned into cash, reinforcing the credibility of reported profits.

Balance Sheet & Cash Flow Health

CONMED Corporation (CNMD) — FCF & Capital Returns

Free Cash Flow Statistics

Buyback & Dividend Trends

A Piotroski score of 6 out of 9 signals solid accounting fundamentals, with positive signals on profitability, leverage reduction, and cash flow generation.
The Altman Z‑score of 1.92 places CONMED in the 'gray' zone, indicating moderate bankruptcy risk; while not alarming, it warrants monitoring given the cyclical nature of healthcare spending.
Free cash flow conversion of 10.98% and an OCF/NI ratio of 3.63 demonstrate that earnings are being efficiently turned into cash, reinforcing the credibility of reported profits.

Executive Insights & Key Takeaways

Key Takeaways

1Y Return

▼ -37.4%

vs S&P -61.0pp

Revenue 3Y CAGR

▲ +9.5%

5Y: +9.8%

Net Margin

3.4%

▲ 3Y ago: -7.7%

ROIC

7.6%

▲ 3Y ago: 3.7%

FCF Margin

11.0%

▲ 3Y ago: 1.1%

Piotroski

6/9

Moderate

CONMED has delivered sub‑par equity performance, falling 37.4% over the past year and lagging the S&P 500 by 61 percentage points, reflecting a volatile environment (40.5% volatility) and a negative Sharpe ratio (-1.03). Despite this price weakness, the company’s top line is expanding modestly at 5.2% YoY and a solid 9.5% three‑year CAGR, underpinned by a healthy gross margin of 52.8% that cushions earnings. Profitability remains thin—net margin just 3.4% and ROE only 4.6%—but cash conversion is improving, with free‑cash‑flow margin near 11% and operating cash flow covering roughly 3.6× net income. The balance sheet is relatively sound: a current ratio of 2.14, debt‑to‑equity of 0.81, and interest coverage of 4.5x suggest the firm can meet short‑term obligations while still financing growth. Together, these fundamentals indicate that while price performance has suffered, underlying cash generation and modest leverage provide a foundation for a potential turnaround if margin expansion or revenue acceleration materializes.

✅ Strengths

Revenue is growing at a 9.5% three‑year CAGR, outpacing the broader medical device sector's average ~6%, indicating that product adoption and market penetration are gaining momentum.
The gross margin of 52.8% is robust for a diversified surgical equipment maker, providing ample headroom to absorb cost pressures and fund R&D without eroding earnings.
Free‑cash‑flow conversion stands at 10.98% of revenue, translating into roughly $154 million of free cash, which supports dividend sustainability and potential share buybacks.

⚠️ Risks

Net profit margin is only 3.4%, implying that a small adverse cost shift or pricing pressure could push the company back into loss territory.
The cash conversion cycle of 213 days is lengthy for a device manufacturer, indicating working‑capital inefficiencies that could strain liquidity if sales slow.
An Altman Z‑score of 1.9 places CONMED in the ‘gray’ zone, signaling heightened default risk relative to peers and suggesting that any deterioration in earnings or leverage could trigger solvency concerns.

CNMD

Related Reports

Visit finexus.net/reports for Valuation, Return & Risk, and other reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.